Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30400934 | 0.88 | IL23R (0.52) | OPRM1OPRD1OPRK1 | |
| SCHEMBL31463658 | 0.87 | OPRM1 (0.53) | OPRM1OPRD1OPRK1CTSB | |
| SCHEMBL29569125 | 0.87 | OPRK1 (0.52) | OPRM1OPRD1OPRK1CTSB | |
| SCHEMBL29530923 | 0.86 | OPRD1 (0.55) | OPRM1OPRD1OPRK1CTSB | |
| SCHEMBL29789569 | 0.85 | OPRK1 (0.54) | OPRM1OPRD1OPRK1 | |
| SCHEMBL30658171 | 0.85 | OPRK1 (0.55) | OPRM1OPRK1 | |
| SCHEMBL30435360 | 0.85 | OPRK1 (0.54) | OPRM1OPRD1OPRK1CTSB | |
| SCHEMBL29568724 | 0.84 | OPRK1 (0.59) | OPRM1OPRD1OPRK1CTSB | |
| SCHEMBL29569067 | 0.84 | OPRK1 (0.50) | OPRM1OPRD1OPRK1CTSB | |
| SCHEMBL2777114 | 0.84 | OPRK1 (0.59) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514937-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2026-01-06 | — | — | US | disclosed |
| US-20240299598-A1 | METHODS FOR DETECTING CCR2 RECEPTORS | WASHINGTON UNIVERSITY (US) | 2024-09-12 | — | — | US | disclosed |
| US-12016935-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230381349-A1 | METHODS AND COMPOSITIONS FOR IMAGING AND TREATING CANCER | WASHINGTON UNIVERSITY (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2022076523-A1 | METHODS AND COMPOSITIONS FOR IMAGING AND TREATING CANCER | WASHINGTON UNIVERSITY (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016935-B2 | Methods for detecting CCR2 receptors | CCR2, CCR1, CCR5 | OPRM1 270/4885OPRD1 533/4885OPRK1 236/4885 |
| US-20240299598-A1 | METHODS FOR DETECTING CCR2 RECEPTORS | CCR2, CCR1, CCR5 | OPRM1 270/4885OPRD1 533/4885OPRK1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.